Ptc Therapeutics (PTCT) Current Deferred Revenue (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Current Deferred Revenue of $1.2 million for Q2 2026, down 87.79% year-over-year from $9.8 million in Q2 2025, and up 139.36% quarter-over-quarter from $498000.0 in Q1 2026.
Ptc Therapeutics (PTCT) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $1.2 million for Q2 2026.
- In Q2 2026, Current Deferred Revenue fell 87.79% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (down 87.79% YoY), while the FY2025 annual figure was $2.0 million, down 62.94% from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $1.2 million, up from $498000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $12.8 million in Q1 2025, with the low at $214000.0 in Q1 2023.
- The 5-year median for Current Deferred Revenue is $1.4 million (2022), against an average of $3.4 million.
- The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue jumped 587.27% in 2024, then sank 96.12% in 2026.
- Ptc Therapeutics' Current Deferred Revenue stood at $1.4 million in 2022, then plunged by 40.71% to $801000.0 in 2023, then surged by 587.27% to $5.5 million in 2024, then plunged by 62.94% to $2.0 million in 2025, then tumbled by 41.57% to $1.2 million in 2026.
- Business Quant data shows PTCT's Current Deferred Revenue at $1.2 million in Q2 2026, $498000.0 in Q1 2026, and $2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.19 Mn |
| Mar 31, 2026 | 498,000.00 |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 9.76 Mn |
| Mar 31, 2025 | 12.83 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Dec 31, 2023 | 801,000.00 |
| Sep 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 1.35 Mn |
| Mar 31, 2021 | 1.90 Mn |
| Dec 31, 2020 | 4.15 Mn |
| Sep 30, 2020 | 6.00 Mn |
| Jun 30, 2020 | 7.70 Mn |
| Mar 31, 2020 | 8.64 Mn |
| Dec 31, 2019 | 11.70 Mn |
| Sep 30, 2019 | 14.31 Mn |
| Jun 30, 2019 | 15.80 Mn |
| Mar 31, 2019 | 5.50 Mn |